Overview

  • Product nameAnti-GFAP antibody
    See all GFAP primary antibodies
  • Description
    Sheep polyclonal to GFAP
  • Tested applicationsSuitable for: WB, ELISA, IHC-P, ICC/IFmore details
  • Species reactivity
    Reacts with: Rat, Human
    Predicted to work with: Mouse, Cow, Cynomolgus monkey
  • Immunogen

    Synthetic peptide:

    H-CKLADVYQAELRELRLRLDQ-OH

    conjugated to KLH, corresponding to amino acids in GFAP. This sequence is conseverd in Human Mouse and Rat.

  • Positive control
    • IHC-P and ICC/IF: Human and Rat brain tissue WB: Human brain homogenate

Properties

Applications

Our Abpromise guarantee covers the use of ab90601 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB
ELISA
IHC-P
ICC/IF
  • Application notesELISA: 1/100 - 1/10000.
    ICC/IF: 1/500 - 1/1000.
    IHC-P: 1/4000 - 1/8000.
    WB: 1/5000 - 1/10000. Predicted molecular weight: 50 kDa.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionGFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells.
    • Tissue specificityExpressed in cells lacking fibronectin.
    • Involvement in diseaseDefects in GFAP are a cause of Alexander disease (ALEXD) [MIM:203450]. Alexander disease is a rare disorder of the central nervous system. It is a progressive leukoencephalopathy whose hallmark is the widespread accumulation of Rosenthal fibers which are cytoplasmic inclusions in astrocytes. The most common form affects infants and young children, and is characterized by progressive failure of central myelination, usually leading to death usually within the first decade. Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures, and psychomotor retardation. Patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course.
    • Sequence similaritiesBelongs to the intermediate filament family.
    • Post-translational
      modifications
      Phosphorylated by PKN1.
    • Cellular localizationCytoplasm. Associated with intermediate filaments.
    • Information by UniProt
    • Database links
    • Alternative names
      • wu:fb34h11 antibody
      • ALXDRD antibody
      • cb345 antibody
      • etID36982.3 antibody
      • FLJ42474 antibody
      • FLJ45472 antibody
      • GFAP antibody
      • GFAP_HUMAN antibody
      • gfapl antibody
      • Glial fibrillary acidic protein antibody
      • Intermediate filament protein antibody
      • wu:fk42c12 antibody
      • xx:af506734 antibody
      • zgc:110485 antibody
      see all

    Anti-GFAP antibody images

    • ab90601, at a 1/4000 dilution, staining GFAP in paraffin embedded Human brain tissue (left image) by Immunohistochemistry. Right image shows negative control: 40X objective.
    • ab90601, at a 1/6000 dilution, staining GFAP in Rat brain tissue (left image) by Immunohistochemistry. Right image shows negative control, 40X objective.
    • ab90601, at a 1/500 dilution, staining GFAP in Human brain tissue by Immunofluorescence. 40X objective.
    • ab90601, at a 1/500 dilution, staining GFAP in Rat brain by Immunofluorescence. 40X objective.
    • Anti-GFAP antibody (ab90601) at 1/6000 dilution + Human brain homogenate at 5 µg

      Predicted band size : 50 kDa

    References for Anti-GFAP antibody (ab90601)

    ab90601 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab90601.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"